ライフサイエンスコーパス: systolic

1 blood pressure: low (systolic <100); normal (systolic 100-139 and diastolic <90); and high (systolic

2 fidence interval (95% CI) (-2.17, -0.41)) in systolic and 0.76 mm Hg (95% CI (-1.39, -0.13)) in diast

3 serum 25(OH)D was negatively associated with systolic and diastolic blood pressure (beta = -0.194; 95

4 6 mo, body weight, waist circumference (WC), systolic and diastolic blood pressure (BP), fasting bloo

5 The 6 primary outcomes were change in systolic and diastolic blood pressure (BP), Short Physic

6 onal age (SGA) offspring had 1-2 mmHg higher systolic and diastolic blood pressure across the life co

7 nt reasons: BMI, waist and hip measurements, systolic and diastolic blood pressure, and triglycerides

8 , coffee PCs were positively associated with systolic and diastolic blood pressure, faecal SCFAs, Bac

9 rse cardiovascular risk profile of increased systolic and diastolic blood pressure, increased C-react

10 Systolic and diastolic blood pressures provide informati

11 UK women without PCOS had higher systolic and diastolic blood pressures, and increased te

12 ggested possible inverse effects of elevated systolic and diastolic BP on large artery stroke.

13 Higher cumulative systolic and diastolic BPs were associated with slower w

14 ading to MIF, as well as its contribution to systolic and diastolic cardiac dysfunction and impaired

15 Training decreased systolic and diastolic central (aortic) blood pressure b

16 deterioration (12 patients), followed by LV systolic and diastolic deterioration (in 5 patients).

17 amethasone were growth restricted and showed systolic and diastolic dysfunction, with an increase in

18 d microvascular function accompanied by both systolic and diastolic dysfunction.

19 aphic studies included left ventricular (LV) systolic and diastolic function and valve hemodynamics a

20 ypertension and diabetes, the improvement in systolic and diastolic function was not secondary to a r

21 thy controls underwent assessment of cardiac systolic and diastolic function, myocardial energetics (

22 including OBP and 24-h ABP, 10 mm Hg higher systolic and diastolic HBP were associated with 5.07 (st

23 It then considers how the control of systolic and diastolic intracellular Ca(2+) concentratio

24 Low LVSWI, reflecting poor left ventricular systolic and diastolic performance, is associated with i

25 mercially available arm cuff device yielding systolic and diastolic readings ((mean+/-SD) mmHg) of (-

26 Circumferential systolic and diastolic strain rates displayed moderate c

27 ng transfusion or intervention, hypotension (systolic arterial pressure <=90 mm Hg), and pneumonia.

28 4), whereas low recruiters experienced lower systolic arterial pressure (P = 0.008).Conclusions: A si

29 dP/dtmax strongly correlated with pulse and systolic arterial pressures and with total arterial stif

30 This was accompanied by reduced systolic augmentation (absolute increase in left ventric

31 rt does not; this is associated with reduced systolic augmentation and exercise tolerance.

32 RESULTS*: Peak systolic blood kinetic energy (male: 4.76 +/- 2.66 mJ; f

33 haemoglobin (HbA1c) <=53 mmol/mol (<=7.0%), systolic blood pressure <140mm Hg, or <130 mm Hg if high

34 atients experienced episodes of hypotension (systolic blood pressure <= 90 mm Hg) before the onset of

35 ria (>=150 to <500 versus <150 mg/g), higher systolic blood pressure (>=140 versus 120 to <130 mmHg),

36 t, was associated with a significantly lower systolic blood pressure (- 1.9 (- 2.7; - 1.1) mmHg in me

37 both 15%; 4-square step test, 2% to 7%), or systolic blood pressure (-3.2 to -4.1 mm Hg).

38 (-0.04% [95% CI, -0.53% to 0.46%]; P = .88); systolic blood pressure (0.78 mm Hg [95% CI, -1.48 to 3.

39 c disadvantage, 45%), body mass index (40%), systolic blood pressure (29%), insulin (20%), physical a

40 ent from the rates among those with elevated systolic blood pressure (3.78 [95% CI, 2.76-4.81]), high

41 0, -0.15, P value = 4.69 x 10-10), automated systolic blood pressure (BP) measurement (beta 0.11, 95%

42 aft failure was associated with postdonation systolic blood pressure (per 10 mm Hg, aHR 1.05, 95% CI

43 m Hg [-10.92 to -2.44 mm Hg]; p = 0.003) and systolic blood pressure (point estimate, -12.36 mm Hg [-

44 een serum posaconazole levels and changes in systolic blood pressure (r = .37, P = .01), a negative c

45 and cerebrovascular disease was mediated by systolic blood pressure (SBP) and blood glucose levels,

46 ; and hemoglobin A1c (HbA1c) of at least 8%, systolic blood pressure (SBP) of at least 140 mm Hg, or

47 tion of a history of hypertension and office systolic blood pressure (SBP) with major adverse cardiov

48 The systolic blood pressure (SBP), diastolic blood pressure

49 would increase NO bioavailability to reduce systolic blood pressure (SBP), improve vascular function

50 ith changes in eGFR, serum creatinine (SCr), systolic blood pressure (SBP), renal hypoxia, and renal

51 dition to age, gender, total-cholesterol and systolic blood pressure (SBP).

52 erial afterload that is out of proportion to systolic blood pressure (SBP).

53 terval: 1.13, 1.37) per 10-mm Hg increase in systolic blood pressure among men aged <=67 years with d

54 modeling on the association between lifetime systolic blood pressure and cognitive function in a comm

55 wide selection for traits, including height, systolic blood pressure and college education, and that

56 hm in the setting of the association between systolic blood pressure and death in older adults.

57 xamined the association between postdonation systolic blood pressure and graft failure.

58 The association between systolic blood pressure and structural progression was c

59 ndpoint was baseline-adjusted change in 24-h systolic blood pressure and the secondary efficacy endpo

60 The primary outcome was reduction in systolic blood pressure at 24 months.

61 of 18.8% of the association between lifetime systolic blood pressure burden and midlife cognitive fun

62 h usual care, was noninferior with regard to systolic blood pressure control at 12 weeks.

63 Intensive treatment to lower systolic blood pressure did not result in a clinically r

64 At 24 months, the mean systolic blood pressure fell by 9.0 mm Hg in the interve

65 REBOA inflation increased systolic blood pressure from 67 (40, 83) mm Hg to 108 (9

66 Mean systolic blood pressure from baseline to 12 months decre

67 point was baseline-adjusted change in office systolic blood pressure from baseline to 3 months after

68 rticipants were randomly assigned (1:1) to a systolic blood pressure goal of less than 120 mm Hg (int

69 0.014) moderated island-specific patterns of systolic blood pressure in multivariate-adjusted models.

70 ilencing PVN TNFR1 prevented the increase in systolic blood pressure induced by AngII.

71 Results from the Systolic Blood Pressure Intervention Trial (SPRINT) show

72 (MCI) in 9361 participants in the randomized Systolic Blood Pressure Intervention Trial, which compar

73 Although postdonation systolic blood pressure is associated with graft failure

74 Prevalence of uncontrolled blood pressure (systolic blood pressure level >140 mm Hg or diastolic bl

75 (87.7%) patients in the control group had a systolic blood pressure lower than 150 mm Hg at 12 weeks

76 The primary outcome was systolic blood pressure lower than 150 mm Hg at 12-week

77 reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were r

78 Fourteen of those patients had a systolic blood pressure of lower than 90mmHg.

79 A high systolic blood pressure PRS was trans-ethnically associa

80 ous renal replacement therapy, hypertension (systolic blood pressure ranging from 140 to 190 mm Hg),

81 al (SPRINT) showed that intensive control of systolic blood pressure significantly reduced the occurr

82 edible interval -6.2 to -1.6) and for office systolic blood pressure the difference was -6.5 mm Hg (-

83 t difference between the two groups for 24-h systolic blood pressure was -3.9 mm Hg (Bayesian 95% cre

84 f the participants was 20 kg/m2 and the mean systolic blood pressure was 115 mm Hg.

85 At baseline, the mean systolic blood pressure was 146.7 mm Hg in the intervent

86 Mean change in systolic blood pressure was 3.4 mm Hg (95% CI, 1.1 to 5.

87 wer by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 m

88 Reduced systolic blood pressure was observed with IF (-4.9 mm Hg

89 pared to sham controls, at one week post-SAC systolic blood pressure was significantly elevated and l

90 ssociation between flavan-3-ol biomarker and systolic blood pressure when compared to normotensive pa

91 land use had 1.5% (95% CI: 0.1, 2.9) higher systolic blood pressure, 2.4% (95% CI: 0.6, 4.3) higher

92 (N-terminal Pro-B-type natriuretic peptide), systolic blood pressure, and diastolic blood pressure co

93 Beat-to-beat heart period, systolic blood pressure, and electromyography impulses w

94 ious risks to fall below dietary risks, high systolic blood pressure, and fasting plasma glucose in r

95 e of IGF-1 (insulin-like growth factor 1) in systolic blood pressure, and the strong causal associati

96 BFM prevented the increase in systolic blood pressure, cardiac weight, and renal damag

97 When applied to body mass index, systolic blood pressure, diastolic blood pressure, and p

98 to baseline covariates: age, height, weight, systolic blood pressure, diastolic blood pressure, curre

99 N=4147) and combined with genetic effects on systolic blood pressure, diastolic blood pressure, mean

100 lipoprotein level, history of hypertension, systolic blood pressure, diastolic blood pressure, tobac

101 terrogation of DBP required us to also model systolic blood pressure, given that the 2 are strongly c

102 HR, systolic blood pressure, HRV and skin conductance recove

103 cohol intake, cheese consumption and average systolic blood pressure, largely disregarding the impact

104 etic scores for the response of 6 CRFs (BMI, systolic blood pressure, LDL cholesterol, HDL cholestero

105 n the final model included respiratory rate, systolic blood pressure, oxygenation, retractions, capil

106 Non-blood biomarkers were systolic blood pressure, resting heart rate and body mas

107 n entered by importance as VLDL cholesterol, systolic blood pressure, smoking, and IDL + LDL choleste

108 Choline was associated with higher systolic blood pressure, TGs, lipopolysaccharide-binding

109 severity indices: doppler mean COA gradient, systolic blood pressure, upper-to-lower-extremity SBP gr

110 sociations with coronary atherosclerosis and systolic blood pressure.

111 IDH, by 2017 ACC/AHA (systolic BP <130 mm Hg, diastolic BP >=80 mm Hg) and by

112 mm Hg, diastolic BP >=80 mm Hg) and by JNC7 (systolic BP <140 mm Hg, diastolic BP >=90 mm Hg) definit

113 rs were significantly lower in patients with systolic BP <95 mm Hg compared with >=130 mm Hg (P for a

114 Patients with systolic BP <95 mm Hg received significantly more often

115 terval [95% CI], 1.23 to 1.83), preoperative systolic BP (aOR, 1.16 per 10-mm Hg increase; 95% CI, 1.

116 ease; 95% CI, 1.10 to 1.66) and preoperative systolic BP (aOR, 1.17; 95% CI, 1.06 to 1.30).

117 s to determine the magnitude of the shift in systolic BP (SBP) among Blacks and Whites from the South

118 y the mean over 2 sequential visits for both systolic BP (SBP) and diastolic BP (DBP), and further as

119 e in normotensive individuals with different systolic BP (SBP) values.

120 to 30 years divided into groups according to systolic BP (SBP): G1 (n = 16), resting SBP <110 mmHg an

121 P (DBP, r(g) = 0.11, P = 3.56 x 10(-06)) and systolic BP (SBP, r(g) = 0.06, P = 0.01), but not pulse

122 tics produced a greater reduction in 24-hour systolic BP (SBP; from 138 to 124 mm Hg) compared with s

123 10), weight (SD -0.12; 95% CI -0.14, -0.09), systolic BP (SD -0.11; 95% CI -0.19, -0.02) and diastoli

124 (MAP) was defined as diastolic BP plus 1/3 (systolic BP - diastolic BP).

125 ent was between toe PAT via the PPG foot and systolic BP [- 0.63 +/- 0.05 (mean +/- SE); p < 0.001 vi

126 causal relationship of lymphocyte count with systolic BP and diastolic BP.

127 Reduction in 24-h systolic BP at 3 years was -8.9 +/- 20.1 mm Hg for the o

128 sages of HF drugs were assessed according to systolic BP categories (<95, 95-109, 110-129, and >=130

129 tion (p = 1.8 x 10-4) and increased maternal systolic BP during pregnancy (p = 2.2 x 10-2).

130 privation 2012 decile of 8 [IQR 6-10]), mean systolic BP fell by 6.55 mm Hg (SD 15.17), and mean dias

131 SNX1 gene were associated with a decrease in systolic BP in response to hydrochlorothiazide (HCTZ).

132 ome analyses, there was a greater decline in systolic BP in the intervention than UC group (-5.0 mm H

133 primary outcome of BP control was defined as systolic BP level lower than 140 mm Hg and diastolic BP

134 years or older with hypertension defined as systolic BP level of 140 mm Hg or higher, diastolic BP l

135 al, which compared intensive versus standard systolic BP lowering (targeting <120 mm Hg versus <140 m

136 nd pulse pressure was observed (eg, adjusted systolic BP mean+/-SE for 1st versus 5th quintile respec

137 This study aimed to investigate the role of systolic BP on the prescription rate and actual dose of

138 defined as a decrease of 20 mm Hg or more in systolic BP or 10 mm Hg or more in diastolic BP after ch

139 y 2000 IU and 800 IU vitamin D3 reduced mean systolic BP over 2 y to a small and similar extent, 2000

140 cular ejection fraction, patients with lower systolic BP receive more HF drugs but at lower dose rela

141 Comparison of postdiet ambulatory systolic BP revealed no difference (P = 0.34), which was

142 all and similar extent, 2000 IU reduced mean systolic BP variability significantly more compared with

143 However, systolic BP variability was significantly reduced with 2

144 instance, the differences in mean change in systolic BP with vitamin D vs no vitamin D and with omeg

145 mbination of preoperative arterial diameter, systolic BP, and left ventricular ejection fraction was

146 nocyte, and neutrophil counts, and increased systolic BP, diastolic BP, and pulse pressure was observ

147 Analyses were performed for systolic BP, diastolic BP, mean arterial pressure, and p

148 elial function, arterial stiffness, systemic-systolic BP, lipids, and inflammatory markers did not di

149 Outcomes included daytime and 24-h mean systolic BP.

150 eptor antagonist (MRA) and with longitudinal systolic BP.

151 able general equilibrium condition where pre-systolic calcium level in the cytosol and in the SR must

152 Compared with the 600-IU group, central-systolic, central-diastolic, and systemic-diastolic BP w

153 Within the test set, myocardial end-systolic circumferential Green strain errors were -0.001

154 Global peak systolic circumferential strain (PSCS) was calculated us

155 d-diastolic diameter was 7.33+/-0.89 cm, end-systolic diameter was 6.74+/-0.88 cm, pulmonary artery s

156 larger left atrium and left ventricular end-systolic diameter, and T-wave inversion/ST-segment depre

157 ventricular ejection fraction (LVEF), LV end-systolic diameter-index (LVESDi), DBP, and RHR were univ

158 in change in LVEF, LV end diastolic and end systolic diameters between the 2 groups.

159 ated measures ANOVA were used to observe the systolic, diastolic, and mean arterial pressure (MAP) co

160 on (59%, 58%, and 46%, respectively), LV end-systolic dimension and volume index, >= moderate tricusp

161 valve surgery, LV ejection fraction, LV end-systolic dimension and volume index, presence of FMR was

162 s after TAC, C-dnO1 mice were protected from systolic dysfunction (assessed by preserved left ventric

163 disruption significantly exacerbated post-IR systolic dysfunction (by ultrasound echocardiography) an

164 om 2004 to 2017, were identified with ES and systolic dysfunction (ejection fraction [EF] <50%), foll

165 ld if there was evidence of left ventricular systolic dysfunction (LVSD) defined as SF < 28% or EF <

166 c cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when l

167 nting with dyspnea who have left ventricular systolic dysfunction (LVSD).

168 ery ligation which, 8-10 weeks later, led to systolic dysfunction (verified echocardiographically) an

169 art failure and death, and the resolution of systolic dysfunction after successful catheter ablation

170 evaluate the prevalence of left ventricular systolic dysfunction among patients who experience their

171 lusion In participants with liver cirrhosis, systolic dysfunction and elevated parameters of myocardi

172 erses preestablished cardiac hypertrophy and systolic dysfunction in mice subjected to transverse aor

173 new-onset heart failure or left ventricular systolic dysfunction is more strongly associated with fu

174 ading cause of death (10 of 17; 59%), and LV systolic dysfunction predicted an adverse outcome.

175 Left ventricular diastolic or systolic dysfunction results in increased preload and af

176 ein thrombosis, is more common, but acute LV systolic dysfunction was noted in ~20%.

177 LV systolic dysfunction was reported in 40% of men (who had

178 tress, which also increased, resulting in LV systolic dysfunction with reductions in ejection fractio

179 ury, left ventricular fibrosis that precedes systolic dysfunction, and a high incidence of ventricula

180 l cardiac function but efficiently prevented systolic dysfunction, apoptosis, and fibrosis, while att

181 Moreover, these mice were protected from systolic dysfunction, hypertrophy, lung congestion, and

182 unacceptable angina, severe left ventricular systolic dysfunction, or high-risk coronary anatomy.

183 evalence of moderate-severe left ventricular systolic dysfunction.

184 gical cardiac remodelling, and diastolic and systolic dysfunction.

185 End-systolic EI of 1.16 best identified the presence of PH,

186 < 0.001) and increased right ventricular end-systolic elastance (+0.72 +/- 0.2 mm Hg/mL; p < 0.001) a

187 Systolic EVV in patients with HCM was 7 mL +/- 5, which

188 llow-up according to tricuspid annular plane systolic excursion (TAPSE) quartiles.

189 entricular function (tricuspid annular plane systolic excursion and right ventricular free wall strai

190 Tricuspid annulus plane systolic excursion decreased and the percentage of moder

191 High Z(va) and low tricuspid annulus plane systolic excursion were associated with worse outcome at

192 , high Z(va) and low tricuspid annulus plane systolic excursion, but not moderate to severe AR or sev

193 a therapeutic strategy to prevent and treat systolic failure in AS.

194 vAS, with median values lowest in those with systolic failure, consistent with reduced energy supply

195 by itself a necessary cause of transition to systolic failure.

196 ulative intensity, a variable indicating the systolic force generated by the ventricle.

197 ers with nonhypertrophied hearts with normal systolic function (normal healthy volunteer, n=30), and

198 gnificant deterioration of right ventricular systolic function and greater tricuspid regurgitation, w

199 led patients with preserved left ventricular systolic function and low symptom burden, and excluded p

200 of cardiac myosin-improves left ventricular systolic function and remodeling and reduces natriuretic

201 viated follow-up, there was good recovery of systolic function but persistence of diastolic dysfuncti

202 demonstrate any significant difference in LV systolic function compared with patients with normal tro

203 re disassembly and improved left ventricular systolic function following myocardial infarction, as de

204 dolinium enhancement occurred with normal LV systolic function in 35% (8/23) of patients with DSP.

205 SevAS) develop otherwise unexplained reduced systolic function is unclear.

206 individuals with preserved left ventricular systolic function is unclear.

207 diastolic function are impaired in obesity, systolic function is usually preserved.

208 Left ventricular (LV) systolic function may be overestimated in patients with

209 ared to monotonic pacing, via improvement in systolic function that persisted beyond the pacing treat

210 hied, non-pressure-loaded hearts with normal systolic function undergoing cardiac surgery and donatin

211 ssociations between SDB and LV diastolic and systolic function using data from 1506 adults aged 18 to

212 ne curve analysis (LV GLS <7.0%, impaired LV systolic function vs. LV GLS >=7.0%, preserved LV systol

213 lic function vs. LV GLS >=7.0%, preserved LV systolic function).

214 tly associated with higher LV mass, lower LV systolic function, and reduced left atrial function over

215 ars later to quantify LV diastolic function, systolic function, and structure.

216 gnificantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of l

217 e required PDE9a inhibitor dose also impairs systolic function, observed as a decline in ventricular-

218 Secondary outcomes included changes in LV systolic function, peak oxygen consumption, and quality

219 results in cardiac hypertrophy and impaired systolic function, which could severely limit the therap

220 n SDB severity and subclinical markers of LV systolic function.

221 gressive ventricular enlargement and reduced systolic function.

222 ved cardiac function through improvements in systolic function.

223 populations with preserved left ventricular systolic function.

224 arterial coupling ratio, reflecting impaired systolic function.

225 le drugs in patients with normal ventricular systolic function.

226 unction, which is not indicated by measuring systolic functional parameters using with a normal cine

227 ics: diastolic (lateral and septal E/e') and systolic (global longitudinal, radial, and circumferenti

228 stolic 100-139 and diastolic <90); and high (systolic >=140 or diastolic >=90).

229 Peripartum cardiomyopathy is a form of systolic heart failure affecting young women toward the

230 Identification of systolic heart failure among patients presenting to the

231 ital heart disease patients with symptomatic systolic heart failure and electrical dyssynchrony, CRT

232 is widely used for the treatment of chronic systolic heart failure and hypertension, and has been de

233 ve pulmonary disease, hypertension, elderly, systolic heart failure, thyroid disease), and CHA(2)DS(2

234 ts impact on the outcome of the SHIFT trial (Systolic HF Treatment With the If Inhibitor Ivabradine T

235 ndothelial cells developed-upon aging-severe systolic hypertension and impaired endothelium-dependent

236 th diabetes, -8.6 +/- 18.7 mm Hg in isolated systolic hypertension, -10.1 +/- 20.3 mm Hg in chronic k

237 age <65 years, with versus without isolated systolic hypertension, with versus without atrial fibril

238 exposure was premorbid blood pressure: low (systolic <100); normal (systolic 100-139 and diastolic <

239 e wall thickness, LV mass, and diastolic and systolic LV function; and a standardized neurocognitive

240 m for females, blood pressure >=130 mmHg for systolic or >=85 mmHg for diastolic, HDL cholesterol <40

241 ADHF was defined as systolic or diastolic dysfunction requiring continuous v

242 After adjustment for HBP, neither systolic or diastolic OBP nor ABP was associated with LV

243 Functional analyses revealed improved systolic performance in A1 compared with A2 and less wal

244 2 to 2.51; p = 0.012), and right ventricular systolic pressure >=50 mm Hg (HR: 2.27; 95% CI: 1.50 to

245 TMG >=8 mm Hg and right ventricular systolic pressure >=50 mm Hg were independently associat

246 vanced liver disease, right ventricular (RV) systolic pressure <40 mm Hg, and normal RV function by e

247 nd 53%, respectively), and right ventricular systolic pressure (32 +/- 11, 45 +/- 15, and 50 +/- 14 m

248 4.9 to 10.5 +/- 3.1 mm Hg), pulmonary artery systolic pressure (from 60.6 +/- 14.2 to 33.8 +/- 10.7 m

249 mes (p = 0.005) and higher right ventricular systolic pressure (p < 0.0001).

250 (P = .92), diastolic pressure (P = .31), or systolic pressure (P = .06) before and after US-triggere

251 n is associated with higher pulmonary artery systolic pressure (PASP) and prevalent echocardiographic

252 Baseline pulmonary artery systolic pressure (PASP) estimated from echocardiography

253 Pulmonary artery systolic pressure (PASP) was determined using Doppler ec

254 Echocardiography-derived pulmonary artery systolic pressure (PASP), pulmonary vascular resistance

255 MR grade and estimated right ventricular systolic pressure at 30 days were improved to a greater

256 .7 to 5.6+/-9.6 mm Hg) and the invasive peak systolic pressure gradient (34+/-12 to 11+/-9 mm Hg).

257 , and baseline RV/LV ratio, pulmonary artery systolic pressure, and modified Miller Score, patients w

258 dP/dt (dP/dt(Min)), mean arterial pressure, systolic pressure, diastolic pressure, and left ventricu

259 lute change in RV/LV ratio, pulmonary artery systolic pressure, modified Miller Score was 0.71, 0.57,

260 in central venous pressure, pulmonary artery systolic pressure, RV/left ventricular ratio, and RV fra

261 blood pressure as well as right ventricular systolic pressure.

262 re, diastolic pressure, and left ventricular systolic pressure.

263 reased systemic as well as right ventricular systolic pressure.

264 nce of methods to quantify right ventricular systolic pressures.

265 Systolic pulmonary artery pressure decreased from 40.5 +

266 Predelivery mean gradient was 11 mm Hg, and systolic pulmonary artery pressure was 32 mm Hg.

267 gmocor XCEL) (n = 5) revealed central aortic systolic pulse (CASP) and central augmentation index (cA

268 rates displayed moderate correlation to peak systolic (r=-0.38, p=0.022) and diastolic vorticity (r=0

269 d-life this association did not occur in the systolic range of 110-140 mmHg.

270 k E wave, and the presence of pulmonary vein systolic reversal.

271 X, involving signs of abnormal diastolic and systolic right ventricular function and compression of t

272 by pulse-wave velocity (PWV), together with systolic (SBP) and diastolic (DBP) blood pressure.

273 ase risk factors collected in mid-adulthood: systolic (SBP) and diastolic blood pressure (DBP), high-

274 s and 1 meta-analysis assessed reductions in systolic (SBP) and diastolic blood pressure from pharmac

275 y measured the effect of dietary patterns on systolic (SBP) and/or diastolic blood pressure (DBP) lev

276 f AT, RT, and CT on endothelial function and systolic (SBP)/diastolic blood pressure (DBP) in individ

277 for confounders, each unit decrease in peak systolic septal mitral annular velocity (Septal S') indi

278 formation of TT during diastolic stretch and systolic shortening serves to mix TT luminal content and

279 The prevalence of the systolic Stacey LVNC criterion was low (3.6%) and did no

280 cipants, the mean LA strain, LA longitudinal systolic strain rate, and LA longitudinal early diastoli

281 .94, and 0.94 for LA strain, LA longitudinal systolic strain rate, and LA longitudinal early diastoli

282 The median inter-site systolic variability was 10 mmHg (IQR 2 to 10 mmHg).

283 cal cohort, 1 in 10 (9.8%) patients had peak systolic velocity values that warranted the diagnosis of

284 placebo, respectively; p < 0.001) and LV end-systolic volume (-26.6 +/- 20.5 ml vs. -0.5 +/- 21.9 ml

285 lar volumes were strongly correlated for end-systolic volume (ESV: Pearson r = 0.99, P < .001), end-d

286 rea [BSA], 25 mL/m(2)); left ventricular end-systolic volume (LVSV), 21 mL (LVSV/BSA, 13 mL/m(2)); st

287 tance (p = 0.003), and right ventricular end-systolic volume (p = 0.020) while right ventricular stro

288 endpoint was change in LV end-diastolic and -systolic volume assessed by cardiac magnetic resonance.

289 lyses, female sex was associated with LV end-systolic volume change (beta=0.12; P=0.003) and a lower

290 etween sex and LV reverse remodeling (LV end-systolic volume change) and sex and the composite outcom

291 The left atrial end-systolic volume index (LAESVI) is a predictor of cardiov

292 n with placebo, empagliflozin reduced LV end-systolic volume index by 6.0 (95% CI, -10.8 to -1.2) mL/

293 Percentage-predicted right ventricular end-systolic volume index can identify a high percentage of

294 fined as an increase in left ventricular end-systolic volume index of >15% at 24 months.

295 A percentage-predicted right ventricular end-systolic volume index threshold of 227% or a left ventri

296 for LV end-diastolic volume index and LV end-systolic volume index were negligible (g<0.10).

297 n, LV end-diastolic volume index, and LV end-systolic volume index.

298 e change from baseline to 36 weeks in LV end-systolic volume indexed to body surface area and LV glob

299 ventricular dilation compared with sham (end-systolic volume, day 2: 40.6 +/- 10.2 muL vs. 23.8 +/- 1

300 Peak systolic vorticity index (male: 0.008 +/- 0.005 rad-m(2)